@article{2124a0b84bfc4c8399cda8f17795b070,
title = "Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2",
abstract = "The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant BA.2 has spread in many countries, replacing the earlier Omicron subvariant BA.1 and other variants. Here, using a cell culture infection assay, we quantified the intrinsic sensitivity of BA.2 and BA.1 compared with other variants of concern, Alpha, Gamma, and Delta, to five approved-neutralizing antibodies and antiviral drugs. Our assay revealed the diverse sensitivities of these variants to antibodies, including the loss of response of both BA.1 and BA.2 to casirivimab and of BA.1 to imdevimab. In contrast, EIDD-1931 and nirmatrelvir showed a more conserved activities to these variants. The viral response profile combined with mathematical analysis estimated differences in antiviral effects among variants in the clinical concentrations. These analyses provide essential evidence that gives insight into variant emergence's impact on choosing optimal drug treatment.",
keywords = "Antiviral, BA.1, BA.2, Casirivimab, Imdevimab, Molnupiravir, Nirmatrelvir, Omicron, SARS-CoV-2, Sotrovimab",
author = "Hirofumi Ohashi and Takayuki Hishiki and Daisuke Akazawa and Kim, {Kwang Su} and Joohyeon Woo and Kaho Shionoya and Kana Tsuchimoto and Shoya Iwanami and Saya Moriyama and Hitomi Kinoshita and Souichi Yamada and Yudai Kuroda and Tsukasa Yamamoto and Noriko Kishida and Shinji Watanabe and Hideki Hasegawa and Hideki Ebihara and Tadaki Suzuki and Ken Maeda and Shuetsu Fukushi and Yoshimasa Takahashi and Shingo Iwami and Koichi Watashi",
note = "Funding Information: VeroE6/TMPRSS2 cells were kindly provided by Dr. Makoto Takeda at Department of Virology III, National Institute of Infectious Diseases. This study was supported by an AMED grant JP20fk0108411 (to K.W.), JP22fk0108645j0001 (to H.O.), Moonshot R&D Grant JPMJMS2021 (to S.I.), JPMJMS2025 (to S.I.), and JST MIRAI (to S.I. and K.W.) Funding Information: VeroE6/TMPRSS2 cells were kindly provided by Dr. Makoto Takeda at Department of Virology III, National Institute of Infectious Diseases. This study was supported by an AMED grant JP20fk0108411 (to K.W.), JP22fk0108645j0001 (to H.O.), Moonshot R&D Grant JPMJMS2021 (to S.I.), JPMJMS2025 (to S.I.), and JST MIRAI (to S.I. and K.W.) Publisher Copyright: {\textcopyright} 2022 Elsevier B.V.",
year = "2022",
month = sep,
doi = "10.1016/j.antiviral.2022.105372",
language = "English (US)",
volume = "205",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
}